Todd Asset Management LLC bought a new position in Novo Nordisk A/S (NYSE:NVO - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 41,100 shares of the company's stock, valued at approximately $2,854,000.
Other large investors also recently modified their holdings of the company. Strategic Investment Solutions Inc. IL lifted its holdings in shares of Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after buying an additional 300 shares during the last quarter. Copeland Capital Management LLC lifted its holdings in shares of Novo Nordisk A/S by 184.8% during the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after buying an additional 255 shares during the last quarter. North Capital Inc. acquired a new position in shares of Novo Nordisk A/S during the first quarter worth approximately $27,000. Park Square Financial Group LLC acquired a new position in shares of Novo Nordisk A/S during the fourth quarter worth approximately $29,000. Finally, Transce3nd LLC acquired a new position in shares of Novo Nordisk A/S during the fourth quarter worth approximately $33,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.
Novo Nordisk A/S Stock Performance
Shares of NYSE:NVO opened at $49.88 on Tuesday. The business's fifty day moving average price is $66.68 and its two-hundred day moving average price is $71.20. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $139.74. The stock has a market capitalization of $222.73 billion, a price-to-earnings ratio of 13.70, a price-to-earnings-growth ratio of 1.75 and a beta of 0.63. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56.
Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. The firm had revenue of $11.69 billion for the quarter, compared to analysts' expectations of $77.51 billion. As a group, analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.
Novo Nordisk A/S Cuts Dividend
The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th will be issued a dividend of $0.4119 per share. This represents a dividend yield of 240.0%. The ex-dividend date is Monday, August 18th. Novo Nordisk A/S's dividend payout ratio is presently 45.05%.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on NVO shares. BNP Paribas started coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They set an "underperform" rating for the company. Dbs Bank cut Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Hsbc Global Res cut Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 31st. HSBC cut Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price objective on the stock. in a research report on Thursday, July 31st. Finally, UBS Group cut Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 5th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $93.67.
Read Our Latest Analysis on Novo Nordisk A/S
About Novo Nordisk A/S
(
Free Report)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.